Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells. MM cells localize to the bone marrow, where cell adhesion-mediated autocrine or paracrine activation of various cytokines, such as interleukin 6, insulin-like growth factor 1, and interferon ␣, results in their accumulation mainly because of loss of critical apoptotic controls. Resistance to apoptosis, a genetically regulated cell death process, may play a critical role in both pathogenesis and resistance to treatment of MM.Abnormalities in regulation and execution of apoptosis can contribute to tumor initiation, progression, as well as to tumor resistance to various therapeutic agents. Apoptosis is executed via 2 main pathways that lead to activation of caspases: the death receptor (extrinsic) pathway and the mitochondrial (intrinsic) pathway. Ionizing radiation and chemotherapeutic agents act primarily through the intrinsic pathway, in which mitochondria play the central role. Various therapeutic modalities that are effective in MM modulate levels of the proapoptotic and antiapoptotic Bcl-2 family of proteins and of inhibitors of apoptosis, expression of which is primarily regulated by p53, nuclear factor B, and STAT (signal transducers and activators of transcription) factors. This review focuses on the key concepts and some of the most recent studies of signaling pathways regulated in MM and summarizes what is known about the clinical role of these pathways.
Introduction
Multiple myeloma (MM) is a malignancy of terminally differentiated B-lymphocytes, also known as plasma cells. MM is characterized by accumulation of a monotypic plasma cell population in the bone marrow (BM), serum and/or urine monoclonal immunoglobulin, and osteolytic lesions. Because MM cells are postgerminal, further mutation does not occur [1] . MM constitutes 10% of the hematopoietic malignancies and ranks just behind non-Hodgkin's lymphoma as the second most common of these diseases in the United States [2] . MM is a malignancy characterized by very slow proliferation of malignant plasma cells, which leads to accumulation of these cells within the bone marrow. The existence of this phenomenon suggests that resistance to apoptosis may play a critical role in both pathogenesis and treatment resistance of MM. Moreover, inducers of apopto-sis not only may have a lethal effect but also may support their immortalization in BM.
Apoptosis is a morphologically and biochemically distinct form of eukaryotic cell death that occurs under a variety of physiological and pathological conditions [3] . Apoptosis is executed via 2 main pathways that lead to the activation of caspases: the death receptor (DR) pathway and the mitochondrial pathway [4] . Caspases are members of a cysteine protease family that are synthesized as inactive zymogens. They are responsible for activation of various cellular proteases and endonucleases. The result of activation is cleavage of structural and regulatory cellular proteins and of nuclear DNA. This process leads to morphologic and biochemical cellular changes that are characteristic of apoptosis. The DR pathway is activated by ligation of members of the tumor necrosis factor (TNF) family, such as Fas ligand (FasL; also called Apo1), TNF-␣, and Apo2 ligand (Apo2L; also called TNF-related apoptosis-inducing factor [TRAIL]), to DR on the plasma membrane. The receptors of these ligands-Fas, TNFR1 (TNF receptor 1), and DR4/DR5-are members of the TNF receptor superfamily, which is characterized by similar, cysteine-rich extracellular domains and homologous cytoplasmic death domains [5] . Binding of these DRs by The mitochondrial pathway is regulated primarily by members of the Bcl-2 family, which comprises both proapoptotic and antiapoptotic proteins. The ratio between these subsets determines the susceptibility of cells to various death signals [4] . All contain at least 1 of the 4 conserved Bcl-2 homology (BH) domains [9] . The antiapoptotic members include Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and Bfl-1/A1, which are characterized by the presence of all 4 BH domains (BH1-BH4). Most members also contain a C-terminal hydrophobic tail, which can target these proteins predominantly to the mitochondria and/or endoplasmic reticulum. These proteins prevent cell death by binding and sequestering proapoptotic proteins. The death promoter members are subdivided according to their function and biochemical structure into multidomain proteins, such as Bax and Bak, that closely resemble Bcl-2 but lack the N-terminal BH4 domain. The other subgroup is represented by BH3-only members that possess the BH3 domain required for binding to other members and for death-promoting activity. The BH3-only proteins include Bik, Bid, Puma/BBC3, and Noxa/APR, each thought to be responsible for transducing a specific cell death signal [10] .
After their activation, Bax and Bak undergo conformational changes that contribute to increased permeability of the outer mitochondrial membrane through formation of pores. Bax and Bak also facilitate the release of cytochrome c (cyto c) and sequential activation of the caspase cascade [11] . Cytosolic cyto c binds the adaptor molecule APAF-1 (apoptotic protease activating factor 1) and caspase 9, forming a macromolecular complex, the apoptosome. This process leads to activation of caspase 9 [12] . Activated caspase 9 cleaves caspase 3, which cleaves and activates the other effector caspases (caspases 6 and 7). Additional molecules released from the mitochondria include apoptosisinducing factor [13] and endonuclease G [14] , which exert their apoptotic activity on nuclei. Smac/Diablo [15] [16] [17] and Omi/HtrA2 [18, 19] facilitate caspase activation by antagonizing molecules belonging to the inhibitor of apoptosis (IAP) family.
A number of recent reviews describe the biology of apoptosis and the clinical applications in MM [1, [20] [21] [22] [23] . We focus on the key concepts and some of the most recent studies that summarize the field of MM apoptosis.
Role of the Mitochondrial Pathway in Apoptosis
Ionizing radiation (IR) and chemotherapeutic agents act primarily through the intrinsic pathway, in which mitochondria play the central role. DNA-damaging agents signal cell death by altering the mitochondrial transmembrane potential (⌬⌿m), activating Bcl-2 family members with subsequent cyto c release, and activating the caspase family of proteins [7, 21] . Bcl-2, frequently expressed in follicular lymphomas bearing the t(14;18) chromosomal translocation, is also widely expressed in many other B-and T-cell lymphomas without involvement of a bcl-2 rearrangement [9, 21] .
The effect of genotoxic agents, such as IR and chemotherapeutic drugs, is directed through the mitochondrial pathway in a p53-dependent manner. BH3-only members of the Bcl-2 family-Bik, Puma, and Noxa-are believed to play a central role in p53-activated cell death [24, 25] . We observed that after IR the BH3-only genes puma, noxa, and bik were upregulated in MM and lymphoma tumor cells. Eight and 16 hours after IR, ribonuclease protection assays indicated dramatic transcriptional induction of Bik, and there were similar changes in protein levels. In contrast, an increase in Noxa messenger RNA (mRNA) levels was observed as early as 0.5 hours after IR, and Puma levels had increased by 4 hours after IR. The differences in kinetics of induction of these BH3-only proteins indicated their distinct role in apoptosis activation in MM cells (M.O., A.A., unpublished data). Because Bid is not activated by IR [7] , the identity of the Bax-and/or Bak-activating BH3-only protein is of great interest.
